S&P Futures
3,947.00 -31.00 (-0.78%) Dow Futures
32,022.00 -297.00 (-0.92%) Nasdaq Futures
12,795.25 -58.75 (-0.46%) Russell 2000 Futures
1,712.90 -19.60 (-1.13%) Crude Oil
67.52 -2.44 (-3.49%) Gold
2,001.30 +5.40 (+0.27%)
Columbia Strategic Income Fund (CSNRX)
- GlobeNewswire
Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022
GARDEN CITY, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive long-term safety data for high concen
- GlobeNewswire
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment Duration of oxygen support was significantly shorter for subjects treated with inhaled NO Trend in shortening of hospital length of stay for patients treated with inhaled NO compared to patients receiving standard supportive treatment GARDEN CITY, N.Y., April 25, 2022 (GLOBE NE
